Related Experiment Video
Updated: Jul 20, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.3K
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
John Andraos1, Harleen Muhar2, Shawn R Smith3
1College of Pharmacy, Western University of Health Sciences, 91766, Pomona, CA, USA. jandraos@westernu.edu.
Reviews in Endocrine & Metabolic Disorders
|August 1, 2023
Summary
Tirzepatide, a dual GLP-1 and GIP receptor agonist, shows comparable efficacy to GLP-1 RAs for glucose control and weight loss. This novel agent may offer a preferred therapeutic option for managing type 2 diabetes and obesity.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor analogs (GLP-1 RAs) are established treatments for type 2 diabetes and obesity.
- Gastric inhibitory polypeptide (GIP) agonists have historically shown limited therapeutic benefits.
Purpose of the Study:
- To compare the efficacy and safety of tirzepatide, a dual GLP-1 and GIP receptor agonist, with GLP-1 RAs.
- To predict the future therapeutic role of tirzepatide in managing metabolic conditions.
Main Methods:
- Review of clinical studies supporting tirzepatide's approval.
- Comparative analysis of tirzepatide versus GLP-1 RAs based on existing data.
Main Results:
- Tirzepatide demonstrates glucose-lowering and weight-loss effects comparable to GLP-1 RAs.
- Adverse effect profiles appear similar between tirzepatide and GLP-1 RAs.
- Emerging evidence suggests tirzepatide may offer superior weight reduction potential.
Conclusions:
- Tirzepatide represents a significant advancement in incretin-based therapies.
- Tirzepatide is positioned as a potentially preferential treatment over GLP-1 RAs for weight management in patients with or without diabetes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
01:23Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
01:06Oral Hypoglycemic Agents: Glinides
186
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
186
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
01:17Oral Hypoglycemic Agents: Sulfonylureas
245
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
245